There are 2789 resources available
586P - Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: ePoster Display
587P - Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)
Presenter: Alicia Morgans
Session: ePoster Display
588P - Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial
Presenter: Klara Kvorning Ternov
Session: ePoster Display
589P - Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Enrique Perez Navarro
Session: ePoster Display
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
595P - Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Casilda Llacer Perez
Session: ePoster Display